STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-04-19
Here’s whether Amgen Inc (AMGN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+0.13% over 10 days); RSI 57 — healthy momentum range; strong 1-year return of +25.7%; 3-month momentum positive (+7.5%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 9.2% off its 52-week high. Score: +5/7.
AMGN is holding above its long-term 200-day MA ($322.56) but has slipped below the 50-day MA ($363.61), pointing to short-term weakness in an otherwise intact trend. An RSI of 56.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +25.7% compares to +35.1% for SPY (trailed the market by 9.4%).
$10,000 invested 1 year ago→ $12,571 today
vs. S&P 500 (SPY) — same period trailed market by 9.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($322.56)
✗Above 50-day MA ($363.61)
✓RSI(14) neutral zone (30–70) — currently 56.5
✓Positive return (+25.7%)
✓Within 10% of period high (−9.2%)
Period Range $355.30
$261.43$391.29
RSI (14) 56.5
0 · OversoldOverbought · 100
Key Metrics
Price$355.30
Period Return+25.7%
Period High$391.29
Period Low$261.43
Drawdown−9.2%
MA-50$363.61
MA-200$322.56
RSI (14)56.5
Avg Volume (30d)2.6M
vs. SPYtrailed by 9.4%
Return Rank#519 of 996
Trend Signals
Price is above the 200-day moving average ($322.56)
Price is below the 50-day moving average ($363.61)